ICAM1 and neoplasm: (63) found that ICAM-1 activates platelets in residual tumor tissue after RFA and promotes vascular permeability in TAECs via VE-cadherin and that anti-platelet and anti-ICAM-1 therapy could prevent progression of HCC after RFA.